Unrelated stem cell transplantation after a reduced intensity conditioning regimen containing high-dose thymoglobulin leads to controllable graft-versus-host disease.

[1]  H. Deeg,et al.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  A. Bacigalupo.  Antithymocyte globulin for prevention of graft-versus-host disease , 2005, Current opinion in hematology.

[3]  B. Löwenberg,et al.  Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. , 2003, Experimental hematology.

[4]  D. Ligeiro,et al.  Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Coppes,et al.  Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis , 2002, Bone Marrow Transplantation.

[6]  B. Storer,et al.  Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors , 2002, Bone Marrow Transplantation.

[7]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.